Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets ...

A novel polycyclic aromatic hydrocarbon derivative hole selective material (4PADNC) has been designed to optimize hole ...

Researchers at the Johns Hopkins Kimmel Cancer Center’s Ludwig Center developed a new treatment that selectively targets ...

Once relegated to the fringes of lifestyle care, obesity drugs have emerged as one of the world's most powerful growth ...

Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets TRBC2-positive T-cell ...

University of Hawaiʻi Cancer Center researchers found in laboratory and animal models that when breast cancers stop ...

It's notable that Ipsen has bolted on more than 20 early-stage programmes since 2020 as part of a push to become a major ...

Ipsen has added a Chinese-developed antibody drug conjugate (ADC) to its pipeline in a deal that could top $1bn, cementing ...

Researchers have developed a TRBC2-targeted antibody-drug conjugate for T-cell lymphomas and leukemias, addressing half of ...

Ipsen gains exclusive global rights, outside of Greater China, for development, manufacturing and commercialization of SIM0613, a ...

A research team shows that environmentally relevant antibiotic levels can greatly accelerate the spread of antibiotic resistance genes.A research ...